Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Revises Profit Forecast

NEW YORK, July 11 - Paradigm Genetics announced yesterday that it had revised its earnings projections for the fourth quarter of 2003 from $.05 to $.06 per share profit to between a loss of $.04 per share and a profit of $.01 cent per share. The original guidance was issued in a year-end conference call held in February.

 

Despite its lowering of projections for profitability, Paradigm now expects to have $13 to $15 million in cash and cash equivalents at the end of 2003, as opposed to the $7 to $9 million projected previously. This new figure includes the $2.5 million line of revolving credit that Paradigm gained as part of its $7.5 million debt financing deal with Silicon Valley Bank of Santa Clara, Calif.The financing deal was also announced yesterday, as reported here.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.